<DOC>
	<DOC>NCT01860846</DOC>
	<brief_summary>This post marketing observational study (PMOS) is designed to collect long-term data on the work productivity and changes in quality of life measurements with anti-Tumor Necrosis Factor therapies in patients with moderate to severe Crohn's disease whom are intolerant or/and unresponsive to conventional therapy.</brief_summary>
	<brief_title>Improvement of Work Productivity and Quality of Life With Anti-Tumor Necrosis Factor (TNF) Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Male or female patients between 1865 years of age with moderately/severely (Crohn's Disease Activity Index 220450) active Crohn's disease with/without fistula formation Patients who are able to provide authorization to use and disclose information related with the study Proven diagnosis of Crohn's Disease in accordance with international diagnostic criteria such as European Crohn's and Colitis Organisation (ECCO) guidelines Patients for whom the physician has initiated Crohn's disease treatment with antiTumor Necrosis Factors in accordance with Turkish Ministry of Health regulations and reimbursements. Subject has a history of any kind of biological therapy and/or antiTumor Necrosis Factor treatments for Crohn's disease or other indications Subject has septic complications (active infection and/or active Tuberculosis, undrained abscess) Patients who have bowel obstructions and fibrotic strictures Subject has received any investigational drug within 30 days prior to the Visit 1 at baseline For any reason, subject is considered by the investigator to be an unsuitable.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Crohn's disease</keyword>
</DOC>